United States Federal Circuit

District court correctly ruled that the patent for Plavix, a drug used to treat or prevent blood-thrombotic events, is valid. Appellee's reference patents do not contain an anticipating disclosure of the subject matter of claim 3 of the patent at issue, and that patent is not void for obviousness.

Appellate Information

• Decided 12/12/2008
• Published 12/12/2008

Judges

• NEWMAN, Circuit Judge., Before NEWMAN, LOURIE, and BRYSON, Circuit Judges.

Court

• United States Federal Circuit

Counsel

• For Appellees:
  
• Evan R. Chesler, Cravath, Swaine & Moore LLP, of New York, NY, argued for plaintiffs-appellees.   With him on the brief were Richard J. Stark and David Greenwald.   Of counsel on the brief were Robert L. Baechtold, John D. Murnane, and William E. Solander, Fitzpatrick, Cella, Harper & Scinto, of New York, NY., Robert B. Breisblatt, Welsh & Katz, Ltd., of Chicago, IL, argued for defendants-appellants.   With him on the brief were Steven E. Feldman, Philip D. Segrest, Jr., and Sherry L. Rollo.   Of counsel on the brief were Robert S. Silver, Manny D. Pokotilow, Bruce J. Chasan, and Mona Gupta, Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., of Philadelphia, PA.